<DOC>
	<DOCNO>NCT00445900</DOCNO>
	<brief_summary>RATIONALE : Giving thalidomide together prednisone cyclophosphamide may lessen symptom cause myelofibrosis myeloid metaplasia . PURPOSE : This phase II trial study side effect well give thalidomide together prednisone cyclophosphamide work treat patient myelofibrosis myeloid metaplasia .</brief_summary>
	<brief_title>Thalidomide , Prednisone , Cyclophosphamide Treating Patients With Myelofibrosis Myeloid Metaplasia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine benefit thalidomide , prednisone , cyclophosphamide alleviate disease-associated anemia , thrombocytopenia , and/or splenomegaly patient myelofibrosis myeloid metaplasia ( MMM ) . - Determine benefit regimen palliate four hypercatabolic constitutional symptom ( i.e. , weight loss , fatigue , drench night sweat , unexplained fever ) patient . - Determine toxicity profile regimen patient . Secondary - Determine effect regimen leukocyte count . - Determine effect regimen bone marrow histology , include microvessel density reticulin fibrosis . - Determine effect regimen intramedullary urinary marker angiogenesis . - Determine effect regimen circulate myeloid progenitor cell quantify CD34+ cell . OUTLINE : Patients receive oral thalidomide , oral prednisone , oral cyclophosphamide ( TPC ) daily day 1-28 . Treatment repeat every 28 day 3 course . After 3 course ( 3 month ) treatment , patient respond TPC therapy may receive oral thalidomide alone daily 3 month absence disease progression unacceptable toxicity . Patients undergo bone marrow aspirate biopsy prior study entry , 6 month start therapy , every 6 month 3 year . Samples analyze microvessel density/angiogenesis study ( i.e. , CD34 immunohistochemical vascular endothelium-specific staining ) determine effect therapy marker bone marrow angiogenesis . After completion study therapy , patient follow every 6 month 3 year . PROJECTED ACCRUAL : A total 22 patient accrue study .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelofibrosis myeloid metaplasia ( MMM ) follow subtypes : Agnogenic myeloid metaplasia Postpolycythemic myeloid metaplasia Postthrombocythemic myeloid metaplasia Must 1 follow MMMrelated condition : Anemia , define hemoglobin &lt; 10 g/dL Iron deficiency must exclude cause Thrombocytopenia , define platelet count &lt; 100,000/mm³ Palpable hepatomegaly splenomegaly No evidence myelofibrosisassociated condition bone marrow , include follow : Metastatic carcinoma Lymphoma Myelodysplasia Hairy cell leukemia Mast cell disease Acute leukemia ( include M7 type ) Acute myelofibrosis No chromosomal translocation ( 9:22 ) bcrabl determine bone marrow chromosome analysis peripheral blood fluorescent situ hybridization ( FISH ) analysis PATIENT CHARACTERISTICS : ECOG performance status 03 Absolute neutrophil count ≥ 750/mm³ Bilirubin ≤ 2 time upper limit normal ( ULN ) , unless elevation due MMM AST ≤ 5 time ULN , unless elevation due MMM Creatinine ≤ 2.5 mg/dL No uncontrolled infection , include tuberculosis No known history positive purify protein derivative ( PPD ) untreated isoniazid therapy Positive PPD normal chest Xray completion fullcourse isoniazid therapy allow No federal medical center inmate incarcerate patient No peripheral neuropathy ≥ grade 2 No comorbid condition use study therapy felt potentially harmful Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception PRIOR CONCURRENT THERAPY : No chemotherapy ( e.g. , hydroxyurea , myelosuppressive therapy ) within past 14 day Prior splenectomy MMM allow No concurrent hematopoietic growth factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>secondary myelofibrosis</keyword>
</DOC>